Senior Vice President, AbbVie and President, Global Allergan Aesthetics

Cosmetic Surgery Market to Hit USD 92.5 Billion by 2033, Fueled by Social Media and Evolving Beauty Trends, says Coherent Market Insights

Dermal Fillers and Botulinum Toxin Market to Hit USD 10.16 Billion by 2033, Driven by Surge in Minimally Invasive Aesthetic Procedures – SNS Insider

U.S. Medical Aesthetics Market to hit US$ 19.34 billion by 2033, (CAGR of 12.6%)

Dermal Fillers Market Size, Share, Growth & Forecast (2025–2032) | Industry Trends & Future Outlook

Director II, eClinical Strategy

AbbVie is a pharmaceutical company focused on discovering and delivering innovative medicines. The Director II of eClinical Strategy will build and manage the next generation of e-Clinical Strategy, focusing on AI and automation, while ensuring interoperability across various functions and stakeholders in clinical trials.

Chairman of the Board and Chief Executive Officer

Vice President, Global Strategy and Pipeline, Allergan Aesthetics

Patent rejected for MNC’s cancer drug; generics likely to enter market

Firms advise on RemeGen’s USD5.6bn AbbVie licensing deal

After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next?

Factbox-Global drugmakers rush to boost US presence as tariff threat looms

AbbVie is dedicated to discovering and delivering innovative medicines to address serious health issues. The Director II, eClinical Strategy will build and steward the next generation of e-Clinical Strategy with a focus on AI/Automation, ensuring an integrated clinical technology and data environment while facilitating collaboration across various stakeholders.

Director Ii, Eclinical Strategy

Director Ii, Eclinical Strategy in united states (1000+)

Director II, eClinical Strategy

Director II, eClinical Strategy